Treats onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). ANDA 76390, held by Pharmazone. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 76390 (Terbinafine Hydrochloride), held by Pharmazone, was first approved by FDA on Jul 2, 2007, with 4 approved supplements and 0 published complete response letters.
Terbinafine tablets are an allylamine antifungal indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE · tablet;oral | Terbinafine Hydrochloride | Rx |
| Jun 28, 2012 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 10, 2012 | Supplement 5Labeling | Approved | None posted |
| Nov 10, 2011 | Supplement 4Labeling | Approved | None posted |
| Sep 20, 2011 | Supplement 3Labeling | Approved | None posted |
| Jul 2, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters